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The Molecular Pathogenesis of Pituitary Adenomas:  
An Update
Xiaobing Jiang, Xun Zhang
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 
Pituitary tumors represent the most common intracranial neoplasms accompanying serious morbidity through mass effects and 
inappropriate secretion of pituitary hormones. Understanding the etiology of pituitary tumorigenesis will facilitate the develop-
ment of satisfactory treatment for pituitary adenomas. Although the pathogenesis of pituitary adenomas is largely unknown, con-
siderable evidence indicates that the pituitary tumorigenesis is a complex process involving multiple factors, including genetic 
and epigenetic changes. This review summarized the recent progress in the study of pituitary tumorigenesis, focusing on the role 
of tumor suppressor genes, oncogenes and microRNAs.
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INTRODUCTION 
Pituitary adenomas are among the most frequent intracranial 
tumors. Series of radiological and autopsy studies suggest a 
prevalence as high as up to 22.5% [1]. The cross-sectional 
studies showed that the prevalence of symptomatic pituitary 
adenomas ranges from 7.76 in 10,000 to 1 in 1,064 individu-
als, a rate which is 3 to 5 times higher than that of previously 
thought [2,3]. Although the majority of pituitary adenomas are 
benign and rarely transform into malignant types, they usually 
behave in an aggressive model due to the mass compression 
and hormone excessive or insufficiency [4]. Surgical resection 
remains the first line treatment for most of the pituitary tumors 
except for prolactinomas, with or without adjuvant radiation 
therapy. However, the invasive pituitary adenomas usually can 
not be controlled by these treatments. Systemic medical treat-
ment seems to be a potential effective alternative, which is 
again hampered by the limited understanding of the mecha-
nism underlining the tumorigenesis of pituitary adenomas. 
Further studies to detail the tumorigenesis will contribute to 
exploring new targets which will be helpful in development of 
novel therapeutic approaches for pituitary adenomas.
MONOCLONAL ORIGIN AND PATHOGENIC 
CHANGES OF PITUITARY ADENOMAS 
Pituitary adenomas are considered to be derived either from 
early progenitor or fully differentiated hormone secreting 
cells, and have been documented as monoclonal expansion of 
a genetically mutated cell, demonstrated using X-chromosome 
inactivation technique [5-8]. However, pituitary adenomas 
usually exhibit distinct properties from malignancies. They 
frequently grow slowly and seldom develop into true malig-
nant neoplasms, although they often are accompanied with a 
range of local invasive behaviors [9]. In addition, the common 
mutations of oncogenes and tumor suppressor genes, present 
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in nonendocrine neoplasms, such as PKC, RAS, P53, and RB, 
are usually absent in pituitary adenomas [9]. However, a num-
ber of oncogenes, tumor suppressor genes and cell cycle me-
diators have been identified to be functionally involved in the 
initiation and progression of pituitary adenomas [4,5,10]. Fur-
thermore, increasing literature has demonstrated recently a 
fundamental role of microRNA (miRNAs) and long noncod-
ing RNAs (lncRNAs) in the pathogenesis of pituitary tumori-
genesis [11,12].
GENETIC MUTATIONS IN PITUITARY 
ADENOMAS
The aryl hydrocarbon receptor interacting protein (AIP) gene 
dominant mutations are most frequently implicated in the 
pathogenesis of familial isolated pituitary adenomas with a 
prevalence of 15% [13]. In addition, the germline mutation of 
this gene has been found in all types of sporadic pituitary ade-
nomas, either functioning of nonfunctioning subtypes, with 
predominance in somatotrophinomas [13-15]. Furthermore, 
AIP mutations seem to be more prominent in patients with 
young age and large tumors [13,16].
  The multiple endocrine neoplasia syndrome type 1 (MEN1) 
gene localizes on the chromosome 11q13, usually acts a tumor 
suppressor [17]. MEN1 syndrome is an autosomal dominant 
familial disorder, about 70% of which bear the MEN1 gene 
mutation. However, only 3.5% of the sporadic pituitary adeno-
mas have been found to contain a MEN1 mutation [17]. There-
fore, mutation of MEN1 may play limited role in sporadic pi-
tuitary adenomas. MEN1 patients without MEN1 mutations 
may have mutations in some other gene. Recently, CDKN1B 
(also known as P27) inactivating germline mutations have 
been described in a family presenting a MEN1 like syndrome 
(now designed as MEN4) [18]. Although one of these muta-
tions was subsequently detected in another MEN1 family, no 
mutation was verified in a large cohort of patients with MEN1 
[19]. Therefore, the mutations of P27 may be less common 
than initially thought.
  The mutation of guanine nucleotide-activating alpha sub-
unit (GNAS) gene is the somatic mutation related to the Mc-
Cune-Albright syndrome [5]. This mutation is also detected in 
about 30% to 40% of sporadic growth hormone (GH) secret-
ing tumors and might be involved in the transition of an ag-
gressive prolactinoma to a GH adenoma [5,20,21]. Similarly, 
the autosomal domain disorder, Carney complex (CNC), is 
mainly caused by the mutation of cAMP-dependent protein 
kinase A type 1 alpha regulatory subunit (PRKAR1A) [22]. Yet 
again, this mutation is not detected in human sporadic pitu-
itary adenomas [23].
 Oncogene  RAS mutation is frequent in nonendocrine malig-
nancies, and most associated with the GTPase domain of the 
protein. However, this mutation is rarely encountered in pitu-
itary adenomas except in some highly aggressive adenomas 
and pituitary carcinomas [24].
EPIGENETIC MODIFICATION IN 
PITUITARY TUMORIGENESIS
The term epigenetic modification refers to a process that influ-
ences the gene expression without changing the DNA se-
quence of the gene. DNA methylation is the most common 
epigenetic modification, which is restricted to the CpG dinu-
cleotides in mammals [25]. The sites with clustered CpG are 
known as CpG islands, which usually encompass the gene 
promoter regions. Inappropriate methylation of CpG islands is 
associated with histone deacetylation and gene silencing. Con-
versely, it is also suggested that modification of histone tails 
may lead to CpG island methylation, and therefore reinforce 
an already established silencing event [25,26]. Many genes si-
lenced by hypermethylation have been found to play a remark-
able role in pituitary tumorigenesis, although the exact mecha-
nisms governing site-specific DNA methylation, histone mod-
ification, and gene silencing remain unclear. 
  Cyclin-dependent kinase inhibitor 2A (CDKN2A, or P16) is 
the first gene reported to be silenced in sporadic pituitary ade-
nomas, caused by the methylation of P16 gene CpGs [26]. The 
frequency of P16 methylation tends to vary in different pitu-
itary adenoma subtypes: it is most popular in nonfunctional 
adenomas, but a rare incidence in somatotrophinomas [26]. 
Death associated protein kinase (DAPK) works as a check-
point in activating p19/p53 cell cycle, whose expression was 
found lost in the majority of pituitary adenomas, especially in 
invasive pituitary tumors. Further studies showed that both 
methylation and deletion of DAPK gene might be responsible 
for its loss of expression [26]. Fibroblastoma growth factor 
(FGF) is critical for the development of pituitary. According to 
the studies from Ezzat group, fibroblastoma growth factor re-
ceptor 2 (FGFR2) was significantly down-regulated in half of 
the human pituitary adenomas, and 45% of the tumors were 
detected with methylated promoter of FGFR2 gene [10]. 
Meanwhile, putative target of FGFR2, melanoma associated 
antigen (MAGE-A), is significantly increased in pituitary ade-Pituitary Tumor Pathogenesis
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nomas, comparing to that in normal pituitary tissue. In consis-
tent, MAGE-3 promoter is hypermethylated in normal pituitary 
tissue but hypomethylated pituitary tumors [10]. More interest-
ingly, the mechanism underlying the estrogen induced MAGE-3 
expression also involves histone modification. Taken together, 
these results suggest that epigenetic manipulation plays a signifi-
cant role in sustaining proper function of FGFR2/MAGE-3 path-
way [10]. In addition, the silencing of growth arrest and DNA 
damage inducible gene 45γ (GADD45γ) and RB1 gene are also 
attributed to the hypermethylation of gene CpG island in pitu-
itary tumors [26,27].
  Maternally expressed gene 3 (MEG3) is highly expressed in 
normal pituitary and the majority of functioning pituitary tu-
mors, but not detected in nonfunctioning pituitary adenomas 
(NFAs) [28]. Further studies showed that there is no deletion or 
mutation in MEG3 gene, but rather that failure of MEG3 ex-
pression is associated with the epigenetic regulation [29]. There 
were two differential methylated regions (DMRs) locating in 
the upstream of MEG3, intergenic (IG), and MEG3-DMR, 
which were believed to control the expression of DLK1-MEG3 
imprinting locus [11]. MEG3-DMR encompasses the promoter 
of MEG3. Bisulfite sequencing revealed that the methylation of 
MEG3 promoter and enhancer was significantly higher in pitu-
itary tumors than that in normal pituitary samples [29]. We also 
found a cAMP response element (CRE) within the MEG3 pro-
moter, and deletion of the CRE could significantly reduce the 
transcription activity. The CRE sequences are CpG dinucleo-
tide rich, which suggests a methylation modification in tran-
script factor binding [30]. The methylation status MEG3-DMR 
is controlled by IG-DMR, whose hypomethylation is essential 
for correct imprinting of the DLK1-MEG3 locus [11]. Recently 
studies showed the methylated IG-DMR was significantly in-
creased in NFAs, and treatment with demethylating agent re-
sulted in re-expression of MEG3 in several tumor cell lines, in-
cluding human breast cancer, meningiomas, neuroblastomas 
and hepatocellular carcinomas [11,29,31].
ONCOGENES, TUMOR SUPPRESSOR 
GENES, AND DEREGULATED CELL 
CYCLES
Oncogenes 
The GNAS mutation leading to GTPase inactivation can in-
crease the level of cAMP, and therefore enhances GH synthe-
sis and secretion [5]. Postzygotic GNAS mutations result in a 
pattern of organ specificity with the features of McCune-Al-
bright syndrome, but only cause pituitary hyperplasia, rather 
than focal adenomas [32]. However, in a recent study, Vort-
meyer et al. [33] found a spectrum of changes in anterior pitu-
itary gland in acromegalic patients with McCune-Albright 
syndrome, including hyperplasia and focal adenoma forma-
tion, which suggests a developmental role of GNAS mutation 
in pituitary gland. Interestingly, GNAS mutation is also sug-
gested to be involved in the transition of an aggressive prolac-
tinoma to a GH adenoma [20]. The relationships between 
GNAS mutation and therapeutic outcomes have been explored in 
several studies; the results, however, are inconsistent [34,35].
  The phosphoinositide 3-kinase (PI3K)/AKT signaling is 
commonly involved in regulating fundamental cellular pro-
cess, including cell proliferation, survival and motility, and 
plays a critical role in human tumorigenesis. Previous studies 
showed that the PI3K/AKT pathway signaling was activated 
and enhanced in pituitary adenomas [36]. Subsequently, so-
matic mutations and amplification of PIK3CA gene were ob-
served in pituitary adenomas, and PIK3CA mutation tended to 
be more prevalent in aggressive and recurrent tumors [37].
  Pituitary tumor transforming gene (Pttg) was originally iso-
lated from rat pituitary tumor cells by differential display, and 
identified as a securin in regulating sister chromatin separation 
during mitosis. Recently, increasingly evidence suggests a 
multifunctional role of PTTG in cell physiology and tumori-
genesis [38]. Increased expression of PTTG is detected in the 
majority of pituitary adenomas, and its expression is positively 
correlated with tumor invasiveness and cell proliferation in-
dex, ki-67. Furthermore, transgenic mice with overexpression 
of Pttg in pituitary develop focal pituitary hyperplasia and ad-
enoma formation. Abnormality in PTTG expression results in 
aneuploidy and chromosomal instability [38]. 
Tumor suppressor genes
GADD45γ, a p53-regulated human gene involved in growth 
suppression and apoptosis, represents the first tumor suppres-
sor involved in pituitary tumorigenesis [39]. Using cDNA rep-
resentational difference analysis, we have discovered that loss 
of GADD45γ expression is present in the majority of human 
pituitary adenomas. Transfection of human GADD45γ cDNA 
into pituitary tumor cell lines results in dramatic decreased 
colony formation, which confirms the tumor suppressing func-
tion of GADD45γ gene [39]. Another GADD45 family mem-
ber, GADD45β, is also found to be repressed in pituitary ade-
noma, and acts as a tumor suppressor [40].
  The AIP protein acts as a tumor suppressor by interacting Jiang X, et al.
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with the aryl hydrocarbon receptor (AHR), heat shock pro-
teins, surviving, and many other proteins [41]. It plays an im-
portant role in modulating cAMP signaling and cellular signal-
ing pathways by modulating the localization of AHR. The 
structure and function AIP protein have been discussed in de-
tail in a recent review [41]. Most intriguingly, emerging stud-
ies discovered that acromegaly patients with AIP mutation re-
sponded less well to somatostatin analogues (SSAs). In agree-
ment with this finding, there was a relatively higher preva-
lence of AIP mutation in sporadic acromegaly patients who 
were diagnosed with SSAs resistant GH secreting tumors [16]. 
All these studies imply a potential role of AIP mutation in the 
effect of SSAs on GH secreting tumors. Recently, Chahal et 
al. [42] suggested a mechanism whereby responsiveness to 
SSAs is via AIP regulation of ZAC1 (zinc finger regulator of 
apoptosis and cell cycle arrest), which is a putative tumor sup-
pressor and usually diminished in adenomas. Increased AIP 
mRNA and protein levels are induced with pretreatment of 
SSAs in vivo and in vitro. Meanwhile, enforced overexpres-
sion of wild-type AIP could upregulate ZAC1 mRNA level; 
and enhanced cell proliferation and colony formation were ob-
served after decreasing ZAC1 by AIP knockdown [42]. 
  MEN1 gene is located on chromosome 11q13 and encodes 
menin protein, which acts a scaffold protein in regulating tran-
scription, genome stability, and cell proliferation [9]. Pituitary 
tumors with MEN1 mutation tend to be larger and more inva-
sive. Based on the fact that a germline loss of heterozygosity 
(LOH) involving chromosome 11q13 is observed in almost 
90% of familial and about 30% of sporadic pituitary adeno-
mas, this LOH is considered as an initial hit followed by 
MEN1 somatic mutation as a second hit that leads to tumor 
formation, according to the Knudsen’s two hit model of tu-
morigenesis [9,17,43]. Although MEN1 mutation plays an im-
portant role in the etiology of human pituitary tumorigenesis, 
the involvement of other genes is highly likely. The proposed 
mechanism whereby MEN1 mutations lead to tumor forma-
tion is by weakening the binding capacity of menin to the oth-
er functional proteins, and therefore altering critical events in 
cell cycle regulation and proliferation [17]. In a MEN1 gene 
deletion, leading to absence of menin, reintroduction of MEN1 
gene replacement could generate menin expression in pituitary 
tumors, and significantly reduce tumor cell proliferation [44]. 
  PRKAR1A is a key component of the cAMP signaling path-
way that has been implicated in endocrine tumorigenesis. 
PRKAR1A mutation is predicted to lead to a premature stop 
codon and nonsense-mediated mRNA decay, thus related to 
increased PKA activity and hence tumorigenesis [45]. About 
60% of CNC is caused by the mutation of PRKAR1A [22]. Up 
to 75% of CNC cases exhibit hypersecretion of prolactin 
(PRL) and GH, but clinical manifestations of acromegaly are 
usually subtle. In the mouse model with tissue specific knock-
out of PRKAR1A, increased prevalence of pituitary adenomas 
with elevated GH level was observed [46].
  Reprimo, a downstream effecter of p53, was also shown re-
cently to be down-regulated in the majority of pituitary adeno-
mas, and exhibited capability of increasing tumor cell apopto-
sis [47]. The potential mechanism responsible for the reprimo 
repression remains unclear.
Deregulated cell cycle
The pRb/E2F pathway plays a critical role in pituitary tumori-
genesis, as it has been clearly shown by experimental mouse 
models [48]. Progress from G1 to S phrase of the cell cycle is 
restrained by the hypophosphorylated Rb, which is in turn me-
diated by upstream CDKs and its inhibitors, CDKIs. A number 
of cell cycle regulators have been supposed to play a role in 
pituitary tumorigenesis, including Rb1, p16, p21, p27, cyclin 
D1, and cyclin E [5,26]. 
  CDK4 and its inhibitor p16 play a vital role in cell cycle 
control by mediating Rb1 pathway. Both p16 and Rb1 are tu-
mor suppressors, and usually silenced by genetic alternation in 
nonendocrine neoplasms. However, both of their diminished 
expressions are ascribed to promoter methylation in pituitary 
adenomas. When the p16 expression is silencing, the phos-
phorylated Rb1 releases bound E2F transcription factors, 
which enable cell cycle progress. Specifically, the frequency 
of p16 methylation tends to be various in different pituitary 
adenoma subtypes, which is most popular in NFAs, but a rare 
incidence in somatotrophinomas. It is also suggested that the 
loss of p16 is an early event of pituitary tumorigenesis [26].
  P27 is another cell cycle inhibitor that regulates transition 
from G1 to S phase of cell cycle. The expression of p27 is re-
duced in pituitary tumors, and mice with p27 gene knockout 
develop organ hyperplasia and pituitary adrenocorticotropic 
hormone (ACTH) secreting tumor [18]. More importantly, the 
loss of p27 expression is consistent with the increased cyclin 
E in pituitary tumors, which implies that cell proliferation is 
enhanced by increased cyclin E, when the cell cycle inhibitor 
p27 is lost. However, the loss of p27 expression has not been 
associated with CDKN1B mutation, which is rarely revealed 
in pituitary adenomas [49]. The p27 protein levels, but not 
mRNA levels, are significantly reduced during progression Pituitary Tumor Pathogenesis
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from normal to neoplastic pituitaries and pituitary carcinomas 
[49]. One potential mechanism is the translational failure of 
p27 mRNA, which is controlled by the protein encoded by 
DKC1, whose mutation could affect the translation of p27 
mRNAs harboring internal ribosomal entry elements [50]. 
  Similarly, cyclin D1, encoded by CCND1, and its assembly 
with CDK4 plays a crucial role in controlling the cell cycle 
progress. Previous study showed a higher CCND1 expression 
in nonfunctional pituitary adenomas [5]. A recent study sug-
gests that the polymorphism of CCND1 gene might be an im-
portant factor in the early stages of the tumor formation [51].
  The high mobility group A (HMGA) protein family mem-
bers are small nonhistone chromatin proteins, which are abun-
dantly expressed during embryogenesis, but absent in normal 
adult tissues [52]. Overexpression of HMGA2 has been de-
tected in pituitary adenomas, and mixed GH and PRL secret-
ing pituitary adenomas were observed in transgenic mice with 
HMGA2 overexpress [53]. Moreover, the level of HMGA2 pro-
tein is positively correlated with the invasiveness and Ki-67 index 
in pituitary adenomas [52]. Subsequent studies discovered that 
HMGA2 could enhance transcription factor E2F1 activity by 
up-regulating cyclin B2, and drove cell cycle into S phrase 
thereafter [53-55]. In addition, HMGA1b and HMGA2 can 
also influence cell cycle by regulating CCNB2 encoding cy-
clin B2 and promote pituitary cells proliferation by directly 
enhancing PIT1 expression [52,56]. Therefore, cell cycle dys-
regulation represents the main mechanism by which HMGA 
proteins induce the development of pituitary adenomas [52]. 
  FGFR2 IIIb, a spliced isoform of FGFR2, is tightly restrict-
ed to be expressed in epithelial cell. FGFR2IIIb is considered 
as a tumor suppressor, which is silenced in pituitary tumors 
because of promoter methylation. FGFR2 IIIb activation using 
its selective ligand FGF7 results in diminished pituitary tumor 
cell cycle progression. Recent study shows that MAGE-A3 
might be a down-stream regulator of FGFR2 IIIb. Downregu-
lation of MAGE-A3 resulted in accumulation of p53 and p21, 
suggesting that FGFR2 IIIb pathway represent an potential 
signaling modulating p53 functions in pituitary adenomas 
[57].
MiRNAs in pituitary adenomas
miRNAs are a class of short noncoding RNAs that posttran-
scriptionally regulate the target mRNAs translation and degra-
dation, by binding to the sequences at 3’ untranslated regions 
[58]. Increasing evidence indicates that miRNAs are com-
monly involved in tumor initiation, progression, as well as 
therapeutic outcomes. Moreover, half of the miRNA genes are 
located in cancer associated genomic regions, emphasizing a 
crucial role of miRNAs in tumor pathogenesis [59].
  Recently, deregulation of miRNAs is also revealed in pitu-
itary adenomas (Table 1). With microarray analysis, many 
miRNAs were shown to be differentially expressed in pituitary 
adenomas comparing to normal pituitary samples, and the al-
tered expression of some miRNAs has been associated with 
tumor diameter, invasiveness, and therapeutic outcome [60-
63]. Moreover, each subtype of the pituitary adenomas tends 
to be characterized with specific miRNA profile. According to 
the report by Bottoni et al. [61], 29 differentially expressed 
miRNAs are used to predict pituitary adenoma types. For ex-
ample, miR-23a, miR23b, and miR-24-2 expression is in-
Table 1. MicroRNAs with Validated Targets Involved in the Pathogenesis of Pituitary Adenomas
MicroRNA Pituitary adenomas Expression Function Validated targets
miR-128a, miR-155 and miR-516a-3p Nonfunctional and GH  
   secreting adenomas
Overexpression Oncogene Wee1-like protein kinase
miR-107 Pituitary adenomas Overexpression Tumor suppressor AIP
miR-326, miR-432, and miR-570  Pituitary adenomas Downexpression Tumor suppressor HMGA2
miR-34b and miR-548c-3p  Pituitary adenomas Downexpression Tumor suppressor HMGA1 and HMGA2 
miR-326 and miR-603  Pituitary adenomas Downexpression Tumor suppressor E2F1
miR-15 , miR-16, miR-26a and miR-196a2 Pituitary adenomas Downexpression Tumor suppressor HMGA2
let-7  Pituitary adenomas Downexpression Tumor  suppressor RAS family proteins and HMGA2
miR-26b  GH secreting adenomas Overexpression Oncogene PTEN
miR-128 GH secreting adenomas Downexpression Tumor suppressor BMI1
GH, growth hormone; AIP, aryl hydrocarbon receptor interacting protein; HMGA, high mobility group A; PTEN, phosphatase and tensin homolog; 
BMI1, B lymphoma Mo-MLV insertion region 1 homolog.Jiang X, et al.
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creased in GH and PRL secreting tumors, but decreased in 
ACTH secreting adenomas and NFAs. Members of miR-30 
family were strongly increased in ACTH secreting adenomas, 
while their level is low in prolactinomas [61].
  By targeting mRNA and controlling mRNA translation and 
degradation, the miRNAs can function with either oncogenic 
or tumor suppressive activity. In nonfunctioning and in GH se-
creting pituitary adenomas, Wee1-like protein kinase, which 
acts as a tumor suppressor protein, was shown to be regulated 
by the overexpressed miRNAs, miR-128a, miR-155 and miR-
516a-3p [64]. In ACTH-secreting adenomas, the expression of 
miR-145, miR-21, miR-15 and miR-16 is suppressed, while 
the level of miR-122 and miR-493 is up-regulated in ACTH 
secreting carcinomas [63,65]. Several contradictory facts re-
main regarding miRNAs in pituitary tumors. For example, 
miR-122 is considered as a tumor suppressor in liver tissue; it 
is however abundantly expressed in ACTH and PRL secreting 
carcinomas [65]. Some miRNAs seem to act as tumor suppres-
sors, despite they are overexpressed in pituitary tumors. For 
example, miR-107 is significantly up-regulated in GH secret-
ing and nonfunctional pituitary adenomas, but its overexpres-
sion inhibits proliferation of rat pituitary adenoma cells. Fur-
thermore, miR-107 could not silence its target gene AIP, which 
implies a compensatory regulation mechanism involved [66].
  The DLK1-MEG3 genomic region contains a maternally 
expressed miRNA cluster, which is considered as the largest 
miRNAs group, among which 53 miRNAs have been identi-
fied [67]. Many of them are differentially expressed in vari-
able pathophysiological processes, and found to be involved 
in the pathogenesis of several malignancies [67]. We detected 
the level of 18 miRNAs located in this cluster in pituitary ade-
nomas. Intriguingly, 13 of them were lost or significantly di-
minished, and two of them (miR-431 and miR-770-5p) were 
slightly higher in NFAs comparing to normal pituitary. In ad-
dition, some of them were capable of tumor suppression [68]. 
The specific roles of these miRNAs in the development of 
NFAs are to be determined in future studies.
  Trisomy of chromosome 12, where HMGA2 gene located, ac-
counts for the HMGA2 overexpression restricted in human pro-
lactinomas [69]. The mechanism responsible for the deregulation 
of HMGA proteins in other subtype pituitary adenomas remains 
elusive. A recent study presented by D’Angelo et al. [70] sug-
gested a miRNA-dependent impairment of HMGA/E2F1 path-
way, which acts as a pro-oncogene signaling in pituitary adeno-
mas. They identified that a set of miRNAs, including miR-34b, 
miR-326, miR-432, miR-548c-3p, miR-570, and miR-603, were 
apparently down-regulated in pituitary adenomas. Further evi-
dence demonstrated that miR-326, miR-432, and miR-570 target 
on HMGA2; miR-34b and miR-548c-3p target on both the 
HMGA1 and HMGA2; and miR-326 and miR-603 target on 
E2F1. Finally, overexpression of these miRNAs in pituitary cell 
lines (HP75, GH3) could inhibit cell growth and retrain the cells 
in the G1 phrase. Similarly, in another study by the same group, 
HMGA proteins are found as direct targets of miR-15, miR-16, 
miR-26a, miR-196a2, and Let-7a [71]. Additionally, suppres-
sions of let-7 family members and of miR15a/miR16 are found 
in most pituitary tumor subtypes [62]. Reduced let-7 expression 
possibly causes upregulation of the human RAS family of onco-
proteins [61], and low level of miR-15a and miR16-1 inversely 
correlates with tumor diameter and directly correlates with the 
secretion of the antineoplastic cytokine p43 [62]. 
  Finally, some miRNAs are of importance for both sustain-
ing normal pituitary development and promoting tumor prolif-
eration. On one hand, miR-26b could up-regulate Pit-1, whose 
loss leads to anterior pituitary retardation, by targeting lym-
phoid enhancer factor 1 (lef-1) [72]. On the other hand, the 
expression of miR-26b is higher in GH-secreting adenomas 
than in normal tissues [73]. MiR-26b enhances the ability of 
pituitary cell lines to form colonies, invade, and formation of 
pituitary xenograft growth, by directly targeting phosphatase 
and tensin homolog (PTEN) gene. Conversely, miR-128, 
which is down-regulated in GH-secreting adenomas, behaves 
an opposite function to miR-26b. More interesting, miR-128 
through BMI1 binding on PTEN promoter indirectly regulates 
PTEN expression, suggesting an interaction with miR-26b in 
controlling PTEN/AKT pathway [73].
Large noncoding RNAs (lncRNAs): MEG3
lncRNAs are a subgroup of noncoding RNAs that are longer 
than 200 nucleotides. Multiple studies have unveiled a central 
role of lncRNAs in human tumorigenesis. MEG3 represents 
the first and the only recognized lncRNA tumor suppressor in 
pituitary adenomas. Update about the structure and function of 
MEG3 in nonfunctioning adenomas and meningiomas has 
been detailed in recent reviews [11,74,75]. This line of studies 
will establish novel and unique mechanisms regarding patho-
genesis of human NFAs and lncRNA biology in general. 
CONCLUSIONS
Pituitary tumorigenesis appears to be a complex process with ex-
trinsic and intrinsic factors involved. Increasing evidence has Pituitary Tumor Pathogenesis
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demonstrated fundamental roles of tumor suppressors, onco-
genes, as well as cell cycle abnormalities in pituitary tumorigen-
esis. MiRNAs and lncRNAs are considered as new emerging 
paradigms in pituitary tumorigenesis. However, the question of 
cause or effect in relation to pituitary adenoma initiation remains 
unanswered, which is largely constrained by the lack of satisfac-
tory human pituitary adenoma cell lines and animal models. 
Therefore, future work is expected in generating workable hu-
man functional and nonfunctional pituitary tumor cell lines, and 
establishing satisfactory animal models, which will be of great 
importance in understanding the molecular events governing pi-
tuitary tumor pathogenesis and providing assay and screening 
models for the development of novel therapeutic approaches. 
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